Eli Lilly price target lowered to $970 from $1,000 at Wells Fargo
Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...
ClearBridge Large Cap Growth ESG Strategy Q4 2024 Commentary
The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.
Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider
Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.
Merck price target lowered to $125 from $130 at Citi
Citi lowered the firm’s price target on Merck (MRK) to $125 from $130 and keeps a Buy rating on the shares. Ahead of the Q4 earnings, the firm ...
TipRanks on MSN21h
AbbVie price target lowered to $205 from $215 at Citi
Citi lowered the firm’s price target on AbbVie (ABBV) to $205 from $215 and keeps a Buy rating on the shares. Ahead of the Q4 ...
S&P 500 rises, Nasdaq jumps 2% in recovery rally after Nvidia-led sell-off: Live updates
The S&P 500 advanced 0.92% to 6,067.70, with technology shares seeing the biggest gains among sectors. The Technology Select ...
Hosted on MSN18h
What Does the Future Hold for Eli Lilly?
GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...